171 related articles for article (PubMed ID: 8174204)
21. Effective use of ribonucleotide reductase inhibitors (Didox and Trimidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS).
Mayhew C; Oakley O; Piper J; Hughes NK; Phillips J; Birch NJ; Elford HL; Gallicchio VS
Cell Mol Biol (Noisy-le-grand); 1997 Nov; 43(7):1019-29. PubMed ID: 9449534
[TBL] [Abstract][Full Text] [Related]
22. Preventive effect of trimidox on oxidative stress in U937 cell line.
Kanno S; Kakuta M; Kitajima Y; Osanai Y; Kurauchi K; Ohtake T; Ujibe M; Uwai K; Takeshita M; Ishikawa M
Biol Pharm Bull; 2007 May; 30(5):994-8. PubMed ID: 17473450
[TBL] [Abstract][Full Text] [Related]
23. Genotoxic properties of the newly synthesized antineoplastic agents amidox, didox and trimidox.
Miadoková E; Macáková K; Podstavková S; Vlcek D
Pharmazie; 1997 Jul; 52(7):540-4. PubMed ID: 9266591
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
van't Riet B; Wampler GL; Elford HL
J Med Chem; 1979 May; 22(5):589-92. PubMed ID: 458812
[TBL] [Abstract][Full Text] [Related]
25. DNA-protective activity of new ribonucleotide reductase inhibitors.
Rauko P; Romanova D; Miadokova E; Macakova K; Novotny L; Elford HL; Szekeres T
Anticancer Res; 1997; 17(5A):3437-40. PubMed ID: 9413183
[TBL] [Abstract][Full Text] [Related]
26. Trimidox induces apoptosis via cytochrome c release in NALM-6 human B cell leukaemia cells.
Kanno S; Uwai K; Tomizawa A; Hiura T; Osanai Y; Ujibe M; Takeshita M; Ohtake T; Kimura K; Ishikawa M
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):44-50. PubMed ID: 16433890
[TBL] [Abstract][Full Text] [Related]
27. In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency disease.
Sumpter LR; Inayat MS; Yost EE; Duvall W; Hagan E; Mayhew CN; Elford HL; Gallicchio VS
Antiviral Res; 2004 Jun; 62(3):111-20. PubMed ID: 15130534
[TBL] [Abstract][Full Text] [Related]
28. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
Carter GL; Cory JG
Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
[TBL] [Abstract][Full Text] [Related]
29. Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase.
Carter GL; Cory JG
Adv Enzyme Regul; 1989; 29():123-39. PubMed ID: 2699151
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of ribonucleotide reductase and growth of human colon carcinoma HT-29 cells and mouse leukemia L1210 cells by N-hydroxy-N'-aminoguanidine derivatives.
Matsumoto M; Fox JG; Wang PH; Koneru PB; Lien EJ; Cory JG
Biochem Pharmacol; 1990 Oct; 40(8):1779-83. PubMed ID: 2242014
[TBL] [Abstract][Full Text] [Related]
31. Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime.
Tihan T; Elford HL; Cory JG
Adv Enzyme Regul; 1991; 31():71-83. PubMed ID: 1877400
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of ribonucleotide reductase and L1210 cell growth by N-hydroxy-N'-aminoguanidine derivatives.
Cory JG; Carter GL; Bacon PE; T'ang A; Lien EJ
Biochem Pharmacol; 1985 Aug; 34(15):2645-50. PubMed ID: 3893440
[TBL] [Abstract][Full Text] [Related]
33. Apoptosis-inducing cleavage of caspases by trimidox, an inhibitor of ribonucleotide reductase.
Fritzer-Szekeres M; Luxbacher C; Horvath Z; Grusch M; Krupitza G; Elford HL; Szekeres T
Adv Exp Med Biol; 2000; 486():125-30. PubMed ID: 11783468
[No Abstract] [Full Text] [Related]
34. Structural aspects of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of L1210 cell growth and ribonucleotide reductase activity.
Cory JG; Cory AH; Raber NK; Narayanan A; Schneller SW
Adv Enzyme Regul; 1993; 33():129-40. PubMed ID: 8356905
[TBL] [Abstract][Full Text] [Related]
35. Trimidox-induced apoptosis is mediated through induction of p53 in NALM-6 cells.
Kanno S; Ohtake T; Osanai Y; Kurauchi K; Ujibe M; Uwai K; Takeshita M; Satoh S; Ishikawa M
J Pharmacol Sci; 2008 Mar; 106(3):521-4. PubMed ID: 18344606
[TBL] [Abstract][Full Text] [Related]
36. Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.
Figul M; Söling A; Dong HJ; Chou TC; Rainov NG
Cancer Chemother Pharmacol; 2003 Jul; 52(1):41-6. PubMed ID: 12690517
[TBL] [Abstract][Full Text] [Related]
37. In vivo growth of mouse leukemia L1210 cells with metabolic alterations in the subunits of ribonucleotide reductase.
Somerville L; Cory AH; Cory JG
In Vivo; 2002; 16(3):175-7. PubMed ID: 12182112
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
Nandy P; Lien EJ; Avramis VI
Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
[TBL] [Abstract][Full Text] [Related]
39. The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model.
Cory JG; Sato A; Carter GL; Bacon PE; Montgomery JA; Brown NC
Adv Enzyme Regul; 1985; 23():181-92. PubMed ID: 3907303
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of ribonucleotide reductase by antitumor agents related to levodopa and dopamine.
FitzGerald GB; Wick MM
Biochem Pharmacol; 1985 Feb; 34(3):353-60. PubMed ID: 3882092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
